Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTSZ6Y3)

• DTT Name: Proto-oncogene c-Ros (ROS1) DTT Info
• Gene Name: ROS1

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[1]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[2]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[4]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AB-106	DMEW62S	Non-small-cell lung cancer	2C25	Phase 2	[5]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

5 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carboxamide derivative 4	DMU5GKC	N. A.	N. A.	Patented	[7]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Solid tumour/cancer	2A00-2F9Z	Patented	[8]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Solid tumour/cancer	2A00-2F9Z	Patented	[8]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Solid tumour/cancer	2A00-2F9Z	Patented	[8]
PMID28270010-Compound-Figure21-b	DM6IYAT	Brain metastases	2D50	Patented	[8]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24432909C8e	DMEGAZS	Discovery agent	N.A.	Investigative	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of AnHeart Therapeutics.
• [6] National Cancer Institute Drug Dictionary (drug id 766123).
• [7] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [8] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [9] Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.